Aged Psychiatry

The Research Unit within Caulfield Aged Psychiatry has experienced its busiest year yet. This is most encouraging, having only commenced work in 2009.

Our main research activities for the year have involved ongoing work on two large, industry-funded clinical trials examining the safety and efficacy of potential disease-modifying concepts in Alzheimer’s disease. Both are sponsored by eli Lilly, and are known as the LZAN and LZAO studies resectively.
A further industry-sponsored Alzheimer’s trial, sponsored by Velacor Therapeutics, commenced in January 2010, with a study sponsored by Prana Biotechnology also due to start in March 2012. The research unit has now established itself as a sought-after site by industry partners, and we receive numerous expressions of interest from big pharmaceutical companies in relation to conducting further research with us.
Recently Janssen Pharmaceuticals have agreed to fund a 50-patient, Melbourne-based study into the effects of the injectable antipsychotic Invega Sustenna on elderly patients with schizophrenia. This is a Caulfield-based initiative and is proposed to involve four other Melbourne-based sites over a two-year period.

Aged Psychiatry team

Team Leader
Dr Andrew Gleason FRANZCP
Clinical Trials Manager
Dr Mary Panjari
Clinical trials Coordinator 

Maree Mastwyk RN RPN
Ms Sue Dal Sasso 
Research Nurse
Ms Jenny Bortoli RN
Ms Jenny Nam 

Aged Psychiatry: current projects

Protocol H8A-MC-LZAN - Effect of Passive Immunisation on the Progression of Alzheimer’s Disease: LY2062430 versus Placebo (Lilly) – concludes June 2012

Protocol H8A-MC-LZAO - Effect of Passive Immunisation on the Progression of Alzheimer’s Disease: LY2062430 versus Placebo. An Open-Label Extension Study (Lilly) – concludes December 2013

A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and the Biological and Cognitive Effects of VEL015 (Sodium Selenate) in Patients with Mild to Moderate Alzheimer’s Disease – a Pilot Study (Velacor Therapeutics) – in progress, recruiting

A randomised, double-blind, placebo-controlled study to assess the safety and tolerability of PBT2, and its effect on amyloid deposition in the brains of patients with prodromal or mild Alzheimer’s disease. (Prana Biotechnology) – commencing March 2012

Neuropsychological Characteristics of Patients Referred With Senile Squalor (self-funded; in progress)

Psychogeriatric nursing homes in Victoria: a comparison of models of care (self-funded; in progress)

Effect on the family carer post-institutionalisation of the patient with dementia (self-funded; awaiting HREC approval)

Effects of regular supervision upon paid professional carers within a nursing home environment (self-funded; awaiting HREC approval)

Effects of an educational programme targeting general practitioners (regarding the management of behaviours of concern) on psychotropic prescribing and adverse outcomes in nursing homes: a pilot study (self-funded; in protocol development)

Efficacy and safety of paliperidone long-acting injection in elderly people with schizophrenia (proposed, involving 5 local sites, external funding secured, in protocol development)

A pilot study to evaluate the use of mobile computing within a community aged psychiatry service (internally funded, in protocol development)